Key result
Regadenoson is a safe and effective pharmacological stress agent for detecting reversible myocardial ischemia, demonstrating non-inferiority to adenosine and offering a favorable safety profile in patients with reactive airway disease and renal impairment.
Why the study?
Regadenoson is the most widely used pharmacological stress agent, but equivocal results exist across certain chronic diseases and its use has not been studied in patients of low socioeconomic class.
Is regadenoson safe and effective for pharmacological stress testing across various patient populations with chronic diseases?
Is regadenoson safe and effective for pharmacological stress testing across various patient populations with chronic diseases?
Regadenoson is a safe, well-tolerated, and widely used pharmacological stress agent for myocardial perfusion imaging, including in patients with reactive airway disease and renal impairment, though evidence is lacking for low socioeconomic and seizure-disorder populations.
Regadenoson suitable as preferred stress agent; reinforces selective A2A agonism over non-selective alternatives in practice and research.
Regadenoson is a pharmacological stress agent that has been widely used since its approval by the Food and Drug Administration (FDA) in 2008. For many years, dipyridamole and adenosine, which are non-selective adenosine receptor agonists, were more popular. However, these agents are less preferred now due to their undesirable adverse effects as compared to regadenoson. In the ADVANCE (ADenoscan Versus regAdenosoN Comparative Evaluation) phase 3 clinical trial, regadenoson demonstrated non-inferiority to adenosine for detecting reversible myocardial ischemia. This review summarizes the clinical utilities of regadenoson as the most widely used pharmacological stress agent. Moreover, the use of regadenoson has been documented in specific patient populations. Although regadenoson has established safety and efficacy in most patients with chronic diseases, there are equivocal results in the literature for other chronic diseases. It is warranted to highlight that the use of regadenoson has not been studied in patients of low socioeconomic class; it is a condition that carries a significant burden on the cardiovascular system.
No takes yet. Share an insight, caveat, or question.
Elkholy et al. (2021) conducted a review in Coronary artery disease. Regadenoson vs. Adenosine was evaluated. Regadenoson is a safe and effective pharmacological stress agent for detecting reversible myocardial ischemia, demonstrating non-inferiority to adenosine and offering a favorable safety profile in patients with reactive airway disease and renal impairment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: